1. In Vivo
  2. >>Archive

At TCT, Cardiology Companies Invade Neurology's Turf

Having gradually chipped away at the patient base of surgeons, where are interventional cardiologists to go next? One answer: neurology. At this year's TCT meeting, two new areas of stroke prevention were discussed as potential growth opportunities. The first area is PFO closure: 25% of people in the general population have a congenital heart wall defect that is associated with cryptogenic stroke. In the other, left atrial appendage occlusion, to eliminate a pouch in the heart that can collect clots that cause stroke in patients with atrial fibrillation.

It is certainly one of interventional cardiology's most striking successes that, over the past decade or so, it has grown in large measure by slowly stealing away patients from cardiac surgeons. Despite stellar clinical success of their own in coronary artery bypass grafting (CABG) surgery, surgeons have watched as interventionalists have extended their domain, moving beyond single vessels to multi-vessel disease. And, armed with a host of new tools and ever more sophisticated techniques, interventionalists now seem ready to tackle cases—in tortuous lesions or total chronic occlusions, for example—long been thought to be the exclusive province of surgeons.

But interventional cardiology's success has created challenges of its own: having gradually chipped away at the patient base of surgeons,...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.